Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rituximab + Zanubrutinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rituximab | Rituxan | IDEC-C2B8|MabThera | CD20 Antibody 25 | Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov). |
Zanubrutinib | Brukinsa | BGB-3111 | BTK inhibitor 38 | Brukinsa (zanubrutinib) inhibits Bruton tyrosine kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing cells (PMID: 31378456). Brukinsa (zanubrutinib) is FDA approved for use in patients with mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05976763 | Phase III | Zanubrutinib Rituximab + Zanubrutinib | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT05735834 | Phase III | Rituximab Rituximab + Zanubrutinib | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ) | Recruiting | SWE | NOR | ITA | GBR | FRA | ESP | DNK | CHE | AUT | 0 |
NCT04002297 | Phase III | Rituximab + Zanubrutinib Bendamustine + Rituximab | Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 6 |
NCT06350318 | Phase II | Rituximab + Zanubrutinib | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Recruiting | USA | 0 |
NCT05635162 | Phase II | Rituximab + Zanubrutinib | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (ZEBRA) | Recruiting | GBR | 0 |
NCT05100862 | Phase III | Rituximab + Zanubrutinib Lenalidomide + Rituximab Obinutuzumab + Zanubrutinib | A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 7 |
NCT06854003 | Phase II | BGB-11417 + Rituximab + Zanubrutinib Bendamustine + Rituximab + Zanubrutinib Cytarabine + Rituximab Rituximab + Zanubrutinib | BRAZAN Trial in Frontline MCL (BRAZAN) | Not yet recruiting | USA | 0 |
NCT04458610 | Phase II | Rituximab + Zanubrutinib | BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient | Active, not recruiting | USA | 0 |